查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726324

全球麻疹、腮腺炎和德國德國麻疹疫苗市場：市場規模、佔有率、趨勢分析（按類型、目標人口、分銷管道和地區）、細分市場預測（2025-2030 年）

Measles, Mumps, Rubella Vaccine Market Size, Share & Trends Analysis Report By Type, By Target Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

麻疹、腮腺炎和德國德國麻疹疫苗市場的成長和趨勢：

根據Grand View Research, Inc.的最新報告，全球麻疹、腮腺炎和德國麻疹疫苗市場規模預計到2030年將達到29.5億美元，2025年至2030年複合年成長率為8.47%。

這一成長得益於政府支持力道的加大和公共衛生宣傳活動的發展。一個關鍵的轉折點出現在 2025 年 4 月，當時長期對疫苗持懷疑態度的美國衛生局局長羅伯特·F·肯尼迪 (Robert F. Kennedy Jr.) 在德克薩斯州爆發麻疹疫情期間公開核准MMR 疫苗。在德克薩斯州發生第二例麻疹死亡病例後，甘迺迪國務卿公開放棄了對 MMR 疫苗的支持。甘迺迪的言論先前曾引發支持者的強烈反對，但在改變公眾看法和強調 MMR 疫苗接種的重要性方面發揮了關鍵作用。這起事件對疫苗宣傳活動起到了推動作用，提高了猶豫不決人群的接種依從性。這可以加強提高疫苗接種率，並最大限度地降低未來疫情爆發的風險，特別是在反疫苗接種情緒日益高漲的地區。

產品核可也是 MMR 疫苗市場的主要成長要素。 2022年6月，葛蘭素史克宣布Priorix已獲得美國食品藥物管理局（FDA）核准，用於12個月及以上兒童的麻疹、腮腺炎和德國德國麻疹主動免疫。 Priorix 已在包括加拿大、澳洲和整個歐洲在內的 100 多個國家獲得批准，並已透過全球 8 億劑接種證明了其可靠性和廣泛用途。 FDA 的核准為美國醫護人員提供了默克公司 MMR II 疫苗的替代品，並增強了供應鏈的彈性，以滿足全球疫情期間不斷成長的需求。更多的選擇也會增加競爭，從而有可能降低成本並提高可用性。此類監管部門的核准不僅證明了新疫苗的安全性和有效性，而且還透過促進醫療專業人員和猶豫不決的個人採用疫苗來擴大整體市場。

政府舉措繼續在推動 MMR 疫苗市場成長方面發揮關鍵作用。 2025 年 2 月，新墨西哥州衛生部推出了專門的線上資源，以應對麻疹病例的驚人成長。該舉措的重點是提高人們的認知、發現當地疫情並教育人們及時接種疫苗的重要性。這代表著州和國家政府利用數位平台教育公民、打擊錯誤訊息和為疫苗接種提供後勤支援的更廣泛趨勢。事實證明，政府主導的宣傳活動、強制學前疫苗接種和增加免疫計畫資金，對於降低疫情風險和確保全部區域預防非常有效。這些努力體現了全球對實現消除麻疹目標的政策承諾，尤其是在新冠疫情期間遭遇挫折之後。政府協調行動對於維持較高的疫苗接種覆蓋率和確保公共衛生工作的成功仍然至關重要。

在亞太地區，當地製造商和公私合作在擴大 MMR 疫苗供應方面發揮關鍵作用。 2023 年 11 月，印度免疫學有限公司 (IIL) 推出了 Mabella 疫苗，這是與越南 Polyvac 研究所合作開發的麻疹-德國麻疹聯合疫苗。這次疫苗發射正值印度人類生物學研究所成立25週年，標誌著印度為公民提供可負擔疫苗的努力取得了重要里程碑。 Mabella 疫苗將支持印度的全民免疫計劃（UIP），該計劃每年惠及數百萬兒童。透過提供國產、經濟高效的疫苗替代品，此次推出的疫苗有可能提高疫苗接種覆蓋率，特別是在服務不足的地區。此外，此類合作顯示了該地區疫苗自給自足和創新的重要性。隨著亞太地區越來越多的國家開發和批准自己的疫苗，該地區的疫苗市場將會蓬勃發展，減少對進口製劑的依賴，並加強醫療保健基礎設施。

對抗局部疫情的疫苗接種計畫也為市場擴張做出了重大貢獻。例如，2024年11月，斯里蘭卡衛生署針對麻疹病例的增加，針對某些地區啟動了特別疫苗接種宣傳活動。這項為期一周的計畫旨在透過快速挨家挨戶部署疫苗來遏制感染的蔓延，並專注於疫苗接種覆蓋率下降的高風險地區。這些有針對性的干涉措施表明，靈活、有針對性的策略可以迅速縮小免疫力差距並防止疾病復發。此類國家努力通常得到世界衛生組織和聯合國兒童基金會等全球衛生組織的支持，進一步擴大了其影響力。這些有針對性的努力對於中低收入國家至關重要，因為這些國家的常規疫苗接種系統可能面臨基礎設施和財政挑戰。這些宣傳活動強調了應對力公共衛生政策的重要性，並表明即使是短期宣傳活動也可以刺激市場需求，支持當地疫苗分發網路並有助於實現全球消除疾病的目標。

麻疹、腮腺炎和德國麻疹疫苗市場：概述

  • 按類型分類，四價疫苗將在 2024 年佔據 57.37% 的收益佔有率，預計在 2025 年至 2030 年期間將顯著成長。這一快速成長的主要驅動力是對綜合疫苗接種解決方案的需求不斷成長，這些解決方案可以透過單劑疫苗預防多種疾病。
  • 根據目標人口，嬰兒/幼兒（9-12 個月）細分市場將在 2024 年佔據 67.96% 的最大市場佔有率，預計在 2025 年至 2030 年間將大幅成長。
  • 按分銷管道分類，疫苗中心和公共衛生診所部門在 2024 年引領市場，佔據 41.65% 的最大市場佔有率。這些公共衛生機構，包括社區健康中心和政府經營的疫苗接種診所，是 MMR 疫苗的主要提供者，尤其是在大多數人口依賴公共醫療保健的地區。印度的全民免疫計畫（UIP）等政府資助的舉措進一步加強了衛生部門在免疫接種方面的重要作用。
  • 北美的麻疹、腮腺炎和德國德國麻疹疫苗市場佔了最大的市場佔有率，這得益於政府的大力努力和不斷擴大的公共衛生舉措，旨在控制疫情並提高整個地區的疫苗接種覆蓋率。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 麻疹、腮腺炎和德國德國麻疹疫苗市場：促進因素、趨勢和範圍

  • 市場區隔和範圍
  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢與展望
  • 市場動態
    • 加強政府疫苗接種計劃
    • 感染再次出現，疾病負擔加重
    • 宣導和教育宣傳活動
  • 市場限制因素分析
    • 疫苗猶豫和錯誤訊息
  • 按類型分類的分析工具
    • 波特五力分析
    • PESTEL分析
  • 市場機會分析
  • 新興市場策略

第4章 麻疹、腮腺炎和德國德國麻疹疫苗市場：按類型估計和趨勢分析

  • 麻疹、腮腺炎和德國德國麻疹疫苗市場：依類型波動分析
  • 按類型
  • 單一值
    • 單價疫苗市場（2018-2030）
  • 三價（混合 MMR）
    • 三價（MMR聯合）疫苗市場（2018-2030）
  • 四價
    • 四價疫苗市場（2018-2030）

5. 麻疹、腮腺炎和德國德國麻疹疫苗市場：按目標人口細分的估計和趨勢分析

  • 麻疹、腮腺炎和德國德國麻疹疫苗市場：按目標人口細分的趨勢分析
  • 目標人口
  • 嬰兒（9個月至12歲）
    • 嬰幼兒市場（9個月至12歲）（2018-2030年）
  • 成人
    • 成人市場（2018-2030）

6. 麻疹、腮腺炎和德國德國麻疹疫苗市場：按通路分類的估值和趨勢分析

  • 麻疹、腮腺炎和德國德國麻疹疫苗市場：通路的波動
  • 按分銷管道
  • 醫院和醫療機構
    • 醫院和醫療機構市場（2018-2030）
  • 疫苗中心和公共衛生診所
    • 疫苗中心和公共衛生診所市場（2018-2030）
  • 小兒科/實用
    • 小兒科和私人診所市場（2018-2030）

7. 麻疹、腮腺炎和德國德國麻疹疫苗市場：區域估計和趨勢分析

  • 麻疹-腮腺炎-德國麻疹疫苗：各地區市場佔有率（2024 年及 2030 年）
  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 北美麻疹、腮腺炎和德國德國麻疹疫苗市場（2018-2030 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲麻疹、腮腺炎和德國德國麻疹疫苗市場（2018-2030）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區麻疹、腮腺炎和德國德國麻疹疫苗市場（2018-2030 年）
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲麻疹、腮腺炎和德國德國麻疹疫苗市場（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲麻疹、腮腺炎和德國德國麻疹疫苗市場（2018-2030 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 戰略地圖
  • 公司市場佔有率分析（2024年）
  • 公司簡介
    • Merck &Co., Inc.
    • GSK
    • Serum Institute of India Pvt. Ltd.
    • Sanofi
    • Shanghai Institute of Biological Products
    • Beijing Institute of Biological Products
    • Biological E Ltd.
    • Sinovac
Product Code: GVR-4-68040-558-2

Measles, Mumps, Rubella Vaccine Market Growth & Trends:

The global measles, mumps, rubella vaccine market size is expected to reach USD 2.95 billion by 2030, registering a CAGR of 8.47% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to increasing government support and public health campaigns. A key turning point was in April 2025, when the U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, publicly endorsed the MMR vaccine amidst a surge in measles outbreaks in Texas. His public reversal and endorsement came after the second measles-related death in the state, drawing significant media attention and spurring nationwide discussion. Although it stirred backlash from segments of his prior supporter base, Kennedy's statement played a vital role in shifting public perception and reinforcing the importance of MMR vaccination. This event served as a catalyst for boosting vaccination campaigns and improving compliance among hesitant populations. High-profile endorsements can create powerful ripple effects across communities, strengthening efforts to increase immunization coverage and minimize the risk of future outbreaks, especially in areas facing rising anti-vaccine sentiment.

Product approval is another major growth driver in the MMR vaccine market. In June 2022, GSK announced that the U.S. Food and Drug Administration (FDA) approved its Priorix vaccine for active immunization against measles, mumps, and rubella in individuals aged 12 months and older. Already licensed in over 100 countries, including Canada, Australia, and across Europe, Priorix has distributed over 800 million doses globally, demonstrating its reliability and widespread use. Its FDA approval provided U.S. healthcare providers with an alternative to Merck's M-M-R II, enhancing supply chain resilience and meeting rising demand amid global outbreaks. The availability of more options also fosters competition, potentially reducing costs and improving accessibility. Regulatory approvals such as this not only validate the safety and efficacy of new vaccines but also expand the overall market by encouraging adoption among both healthcare professionals and hesitant individuals.

Government initiatives continue to play a central role in driving the MMR vaccine market growth. In February 2025, the New Mexico Department of Health launched a dedicated online resource in response to an alarming rise in measles cases. This initiative focused on raising awareness, identifying local outbreaks, and educating the public about the importance of timely vaccination. It represents a broader trend in which state and national governments are leveraging digital platforms to enhance public engagement, address misinformation, and support immunization logistics. Government-led awareness campaigns, school-entry vaccine requirements, and increased funding for immunization programs are proving effective in mitigating outbreak risks and ensuring community-wide protection. Such efforts reflect a global policy commitment to achieve measles elimination targets, especially after setbacks during the COVID-19 pandemic. Coordinated government action remains critical in maintaining high vaccination rates and ensuring the success of public health efforts.

In the Asia Pacific region, local manufacturers and public-private collaborations are playing a vital role in expanding MMR vaccine accessibility. In November 2023, Indian Immunologicals Limited (IIL) launched the Mabella vaccine-a measles and rubella combination vaccine developed in partnership with the Polyvac Institute of Vietnam. This launch coincided with the 25th anniversary of the Human Biologicals Institute and marked a significant milestone in India's efforts to provide affordable vaccines to its population. The Mabella vaccine supports India's Universal Immunization Programme (UIP), which targets millions of children annually. By offering a domestically produced, cost-effective alternative, this launch has the potential to strengthen vaccination coverage, especially in underserved regions. Moreover, such collaborations signify the importance of regional vaccine self-sufficiency and innovation. As more countries in Asia Pacific develop and license their own vaccines, the regional market is set to grow rapidly, reducing dependency on imported formulations and boosting health infrastructure.

Targeted immunization programs in response to localized outbreaks also contribute significantly to market expansion. For example, in November 2024, Sri Lanka's Ministry of Health initiated a special vaccination campaign targeting specific districts following a rise in measles cases. This week-long program focused on high-risk areas where immunization coverage had declined and aimed to contain the spread through rapid, door-to-door vaccine deployment. These focused interventions showcase how agile, targeted strategies can rapidly close immunity gaps and prevent disease resurgence. Such national initiatives often receive support from global health organizations like the WHO and UNICEF, further amplifying their impact. In low- and middle-income countries, where routine vaccination systems may face infrastructural or funding challenges, these targeted drives are crucial. They highlight the importance of responsive public health policies and demonstrate how even short-term campaigns can fuel market demand, support local vaccine distribution networks, and contribute to global disease elimination goals.

Measles, Mumps, Rubella Vaccine Market Report Highlights:

  • Based on type, the tetravalent segment accounted for the largest revenue share of 57.37% in 2024 and is anticipated to witness significant growth from 2025 to 2030. This surge is primarily fueled by the growing demand for comprehensive immunization solutions that provide protection against multiple diseases in a single dose.
  • Based on the targeted population, the infants and children (9 months to 12) segment dominated with the largest market share of 67.96% in 2024, and is anticipated to witness significant growth from 2025 to 2030, driven by increasing global immunization efforts and heightened awareness of vaccine-preventable diseases.
  • In 2024, the vaccine centers and public health clinics segment led the distribution channel category, capturing the largest market share at 41.65%. These public health facilities-including community health centers and government-run vaccination clinics-serve as primary providers of MMR vaccines, particularly in areas where public healthcare is the mainstay for most of the population. Their pivotal role in immunization delivery is further bolstered by government-funded initiatives, such as India's Universal Immunization Programme (UIP), which has played a critical part in broadening access to vaccines across the country.
  • The North American measles, mumps, and rubella vaccine market holds the largest market share, fueled by strong government efforts and expanded public health initiatives aimed at controlling outbreaks and increasing vaccination coverage across the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Targeted Population
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Targeted Population outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Measles, Mumps, Rubella Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Strengthened government immunization programs
    • 3.4.2. Resurgent outbreaks and rising disease burden
    • 3.4.3. Public awareness and education campaigns
  • 3.5. Market Restraint Analysis
    • 3.5.1. Vaccine hesitancy and misinformation
  • 3.6. Type Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. Market Opportunity Analysis
  • 3.8. Market Emerging Strategies

Chapter 4. Measles, Mumps, Rubella Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Measles, Mumps, Rubella Vaccines Market: Type Movement Analysis
  • 4.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Type
  • 4.3. Monovalent
    • 4.3.1. Monovalent Market, 2018 - 2030 (USD Million)
  • 4.4. Trivalent (combined MMR)
  • 4.5. Tetravalent
    • 4.5.1. Trivalent (combined MMR) Market, 2018 - 2030 (USD Million)
  • 4.6. Tetravalent
    • 4.6.1. Tetravalent Market, 2018 - 2030 (USD Million)

Chapter 5. Measles, Mumps, Rubella Vaccines Market: Targeted Population Estimates & Trend Analysis

  • 5.1. Measles, Mumps, Rubella Vaccines Market: Targeted Population Movement Analysis
  • 5.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Targeted Population
  • 5.3. Infants and Children (9 months to 12)
  • 5.4. Adults
    • 5.4.1. Infants and Children (9 months to 12) Market, 2018 - 2030 (USD Million)
  • 5.5. Adults
    • 5.5.1. Adults Market, 2018 - 2030 (USD Million)

Chapter 6. Measles, Mumps, Rubella Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Measles, Mumps, Rubella Vaccines Market: Distribution Channel Movement Analysis
  • 6.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Distribution Channel
  • 6.3. Hospitals and Healthcare Institutions
    • 6.3.1. Hospitals and Healthcare Institutions Market, 2018 - 2030 (USD Million)
  • 6.4. Vaccine Centers and Public Health Clinics
    • 6.4.1. Vaccine Centers and Public Health Clinics Market, 2018 - 2030 (USD Million)
  • 6.5. Pediatric and Private Healthcare Clinics
    • 6.5.1. Pediatric and Private Healthcare Clinics Market, 2018 - 2030 (USD Million)

Chapter 7. Measles, Mumps, Rubella Vaccines Market: Regional Estimates & Trend Analysis

  • 7.1. Measles, Mumps, Rubella Vaccines Market Share By Region, 2024 & 2030
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Regional Market Dashboard
  • 7.4. Global Regional Market Snapshot
  • 7.5. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.6. North America
    • 7.6.1. North America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.2. U.S.
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. U.S. Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.3. Canada
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Canada Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.4. Mexico
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Mexico Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7. Europe
    • 7.7.1. Europe Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.2. UK
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. UK Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.3. Germany
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Germany Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.4. France
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. France Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.5. Italy
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Italy Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.6. Spain
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Spain Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.7. Denmark
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Denmark Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.8. Sweden
      • 7.7.8.1. Key Country Dynamics
      • 7.7.8.2. Competitive Scenario
      • 7.7.8.3. Regulatory Framework
      • 7.7.8.4. Sweden Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.9. Norway
      • 7.7.9.1. Key Country Dynamics
      • 7.7.9.2. Competitive Scenario
      • 7.7.9.3. Regulatory Framework
      • 7.7.9.4. Norway Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8. Asia Pacific
    • 7.8.1. Asia Pacific Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.2. Japan
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Japan Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.3. China
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. China Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.4. India
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. India Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.5. Australia
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Australia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.6. Thailand
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Thailand Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.7. South Korea
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. South Korea Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9. Latin America
    • 7.9.1. Latin America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.2. Brazil
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. Brazil Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.3. Argentina
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Argentina Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10. MEA
    • 7.10.1. MEA Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.2. South Africa
      • 7.10.2.1. Key Country Dynamics
      • 7.10.2.2. Competitive Scenario
      • 7.10.2.3. Regulatory Framework
      • 7.10.2.4. South Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.3. Saudi Arabia
      • 7.10.3.1. Key Country Dynamics
      • 7.10.3.2. Competitive Scenario
      • 7.10.3.3. Regulatory Framework
      • 7.10.3.4. Saudi Arabia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.4. UAE
      • 7.10.4.1. Key Country Dynamics
      • 7.10.4.2. Competitive Scenario
      • 7.10.4.3. Regulatory Framework
      • 7.10.4.4. UAE Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.5. Kuwait
      • 7.10.5.1. Key Country Dynamics
      • 7.10.5.2. Competitive Scenario
      • 7.10.5.3. Regulatory Framework
      • 7.10.5.4. Kuwait Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Strategy Mapping
  • 8.4. Company Market Share Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GSK
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Serum Institute of India Pvt. Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Sanofi
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Shanghai Institute of Biological Products
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Beijing Institute of Biological Products
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Biological E Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Sinovac
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Table

  • Table 1 List of abbreviations
  • Table 2 Global Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 4 Global Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Measles, Mumps, Rubella Vaccines Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 9 North America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 12 U.S. Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 15 Canada Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Europe America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 19 Europe America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 UK Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 UK Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 22 UK Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 25 Germany Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 France Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 France Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 28 France Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Italy Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 31 Italy Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Spain Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 34 Spain Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Denmark Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 37 Denmark Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Sweden Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 40 Sweden Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Norway Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 43 Norway Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Japan Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 50 Japan Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 China Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 53 China Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 India Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 India Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 56 India Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Australia Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Australia Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 59 Australia Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Thailand Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 62 Thailand Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 South Korea Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 South Korea Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 65 South Korea Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Latin America Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 69 Latin America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Brazil Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 72 Brazil Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Mexico Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 75 Mexico Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 78 Argentina Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by type, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 85 South Africa Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 91 UAE Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Measles, Mumps, Rubella Vaccines Market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Measles, mumps, rubella vaccines market: Type movement analysis
  • Fig. 15 Measles, mumps, rubella vaccines market: Type outlook and key takeaways
  • Fig. 16 Monovalent market estimates and forecast, 2018 - 2030
  • Fig. 17 Trivalent (combined MMR) market estimates and forecast, 2018 - 2030
  • Fig. 18 Tetravalent market estimates and forecast, 2018 - 2030
  • Fig. 19 Measles, mumps, rubella vaccines market: Targeted Population movement analysis
  • Fig. 20 Measles, mumps, rubella vaccines market: Targeted Population outlook and key takeaways
  • Fig. 21 Infants and children (9 months to 12) market estimates and forecast, 2018 - 2030
  • Fig. 22 Adults (catch-up vaccination) market estimates and forecast, 2018 - 2030
  • Fig. 23 Measles, mumps, rubella vaccines market: Distribution channel movement analysis
  • Fig. 24 Measles, mumps, rubella vaccines market: Distribution channel outlook and key takeaways
  • Fig. 25 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 26 Hospitals and healthcare institutions market estimates and forecast, 2018 - 2030
  • Fig. 27 Vaccine centers and public health clinics market estimates and forecast, 2018 - 2030
  • Fig. 28 Pediatric and private healthcare clinics market estimates and forecast, 2018 - 2030
  • Fig. 29 Regional outlook, 2024 & 2030
  • Fig. 30 Global Measles, Mumps, Rubella Vaccines Market: Region movement analysis
  • Fig. 31 North America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 38 France Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)